Empirical evaluation of very large treatment effects of medical interventions

JAMA

Volumn 308, Issue 16, 2012, Pages 1676-1684

  Pereira, Tiago V ^a   Horwitz, Ralph I ^b,c   Ioannidis, John P A ^d,e  

^a Oswaldo Cruz German Hospital   (Brazil)

^b GLAXOSMITHKLINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD LAW SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; EFFECT SIZE; EXTRACORPOREAL OXYGENATION; INTERVENTION STUDY; META ANALYSIS (TOPIC); MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPIRATORY FAILURE; VALIDATION PROCESS;

EID: 84867731905     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.13444     Document Type: Article

References (36)

1. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.
2. Kent DM, Trikalinos TA. Therapeutic innovations, diminishing returns, and control rate preservation. JAMA. 2009;302(20):2254-2256.
3. Djulbegovic B. The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research. Cancer Control. 2009;16(4):342-347.
4. Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295-300.
5. Durrheim DN, Reingold A. Modifying the GRADE framework could benefit public health. J Epidemiol Community Health. 2010;64(5):387.
6. Ioannidis JP. Why most discovered true associations are inflated. Epidemiology. 2008;19(5):640-648.
7. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. BMJ. 2008;336(7658):1413-1415.
8. Guyatt GH, Oxman AD, Sultan S, et al; GRADE Working Group. GRADE guidelines: 9. rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311-1316.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
10. Pereira TV, Ioannidis JP. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. J Clin Epidemiol. 2011;64(10):1060-1069.
11. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ. 2001;322(7280):226-231.
12. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.
13. Eskola J, Käyhty H, Takala AK, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med. 1990;323(20):1381-1387.
14. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2009;(4):CD000213.
15. Tiong LU, Davies R, Gibson PG, et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev. 2006;(4):CD001001.
16. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev. 2008;(3):CD001340.
17. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2):CD004403.
18. Gan T,Wu Z, Tian L, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane Database Syst Rev. 2010;(1):CD005096.
19. Swingler GH, Michaels D, Hussey GG. WITHDRAWN: conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev. 2009;(4):CD001729.
20. Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database Syst Rev. 2007;(3):CD006000.
21. Giljaca V, Poropat G, Stimac D, Gluud C.Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2010;(5):CD004385.
22. Lede R, Duley L. Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database Syst Rev. 2005;(3):CD002857.
23. Wang X, Liu R, Ma B, et al. High-dose rate versus low-dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev. 2010;(7):CD007563.
24. Yang X, Zeng X, Wu T. Chuanxiong preparations for preventing stroke. Cochrane Database Syst Rev. 2010;(1):CD006765.
25. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion vs bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005;(3):CD003178.
26. Hemilä H, Koivula TT. Vitamin C for preventing and treating tetanus. Cochrane Database Syst Rev. 2008;(2):CD006665.
27. Krum H, Tonkin A. Why do phase III trials of promising heart failure drugs often fail? the contribution of "regression to the truth." J Card Fail. 2003;9(5):364-367.
28. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613.
29. Albert JM, Ioannidis JP, Reichelderfer P, et al. Statistical issues for HIV surrogate end points: point/counterpoint: an NIAID workshop. Stat Med. 1998;17(21):2435-2462.
30. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points - the challenge of statistical validation. Nat Rev Clin Oncol. 2010;7(6):309-317.
31. Farmer AJ, Perera R, Ward A, et al. Meta-analysis of individual patient data in randomised trials of self-monitoring of blood glucose in people with non-insulin treated type 2 diabetes. BMJ. 2012;344:e486.
32. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? picking signal from noise. BMJ. 2007;334(7589):349-351.
33. Prasad V, Gall V, Cifu A. The frequency of medical reversal. Arch Intern Med. 2011;171(18):1675-1676.
34. Prasad V, Cifu A, Ioannidis JP. Reversals of established medical practices: evidence to abandon ship. JAMA. 2012;307(1):37-38.
35. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15(3):369-390.
36. Thorlund K, Devereaux PJ, Wetterslev J, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol. 2009;38(1):276-286.